Clinical effects of docetaxel combined with compound tegafur capsule in the treatment of 38 patients with anthracycline-refractory recurrent metastatic breast cancer
10.3760/cma.j issn.1006-9801.2011.12.004
- VernacularTitle:替吉奥联合多西紫杉醇治疗蒽环类耐药的复发转移性乳腺癌38例
- Author:
Can WU
;
Hongwei XIAO
;
Yuandong LI
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Antineoplastic combined chemotherapy protocl;
Docetaxel;
Compound tegafur capsule
- From:
Cancer Research and Clinic
2011;23(12):804-806
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the efficacy and toxicity of docetaxel combined with compound tegafur capsule(S-1)on anthracycline-refractory recurrent metastatic breast cancer (ARMBC).Methods Thirty-eight ARMBC patients were given intravenous 70 mg/m2 docetaxel at day 1,and oral 60 mg/m2 S-1twice every day at day 1 to 14.Every 3 weeks was one cycle and each patient received at least two cycles.ResultsAfter treatment,among these 38 patients,there was 2 complete response (CR) (5.3 ％),20 partial response (PR) (52.6 ％),10 stable disease (SD) (26.3 ％),and 6 progressive disease (PD) (15.8 ％).Overall objective response rate was 57.9 ％ (95 ％ confidence intervaal: 42.6 ％-74.2 ％) while clinical benefit response rate was 73.7 ％ (95％ confidence interval: 58.4 ％-89.1％).The median time to progression (TTP) was 7.8 months(95 ％ confidence interval:6.7-8.9 months),and median overall survival time(OS)was 15.7 months (95 ％ confidence interval: 12.9-18.8 months).The main toxic reaction was myelosuppression,and grade Ⅲ and Ⅳ adverse events including leucopenia occurred in 21.1％ of all cases.Most common grade Ⅰ and Ⅱ adverse events,such as hand-foot syndrome,nausea,vomiting,diarrhea,liver dysfunction,and oral mucositis,were tolerable.ConclusionGood clinical efficacy is achieved in the therapy of metastatic breast cancer with docetaxel and S-1 combination regimen and toxic reaction is tolerable.
